All Updates

All Updates

icon
Filter
Partnerships
Generate Biomedicines and Amgen enter into USD 1.9 billion research collaboration
AI Drug Discovery
Jan 6, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
AI Drug Discovery

AI Drug Discovery

Jan 6, 2022

Generate Biomedicines and Amgen enter into USD 1.9 billion research collaboration

Partnerships

  • Pennsylvania-based AI drug development company Generate Biomedicines has entered into a USD 1.9 billion worth multi-target, multimodality research collaboration with US biotechnology company Amgen to discover and develop protein therapeutics. 

  • The duo will initially work on developing five clinical targets across various therapeutic areas and modalities, and will also have the option to collaborate on an additional five programs later on. The partnership will leverage Generate’s AI technology and wet lab capabilities as well as Amgen’s protein engineering expertise. 

  • Generate will receive an upfront payment of USD 50 million for the first five programs, followed by up to USD 370 million in additional milestones and royalty payments for each project, totaling USD 1.9 billion. Amgen will also participate in one of Generate’s future financing rounds—the most recent one being a USD 370 million Series B round in November 2021.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.